La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Elicio Therapeutics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Elicio Therapeutics..

Elicio Therapeutics (NASDAQ:ELTX) Azioni, Catena delle Opzioni

Elicio Therapeutics

Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants, and vaccines for an array of aggressive cancers. It has developed its cancer vaccine product candidates to target biologically validated tumor mutation drivers using known neoantigens.

Elicio Therapeutics Inc

Macro Economic Events

Politics

Economics

General

Updated Electoral Vote Count As Of 8:20 p.m. ET: AP Projects Trump With 95 Electoral Votes, Harris With 35 Electoral Votes

As polls begin to close on the East Coast for the 2024 presidential election, the nation waits to see if Donald Trump or Kamala Harris will secure a historic victory.
Trump has secured Kentucky and Indiana, while Harris has won Vermont, according to the Associated Press. With 34% of votes counted in Kentucky, Trump leads with 64.6%. In Indiana, with 24% of votes counted, Trump holds 64%. Meanwhile, with 20% of Vermont&#8217;s votes tallied, Harris has 69%.
In Kentucky, Trump received the endorsement of Senate GOP Leader Mitch McConnell (R-Ky.) despite their previous differences over the Jan.6 Capitol Riots, noted AP.
Vermont is considered a Democrat stronghold and the state&#8217;s Republican Governor Phil Scott voted Democrat in this election, according to the report.
Trump&#8217;s former Vice President and former Indiana Governor Mike Pence <a href="https://www.benzinga.com/news/24/03/37764902/no-surprise-former-trump-ally-refuses-to-endorse-ex-president-in-2024-cites-differences-in-conservat">did not endorse</a> him in the 2024 run but the Hoosier State is a reliable GOP stronghold where the party has held the governor&#8217;s office for the past two decades.
West Virginia voted for Trump for the third straight presidential election cycle as well. No democrat has won the presidential election in the state since Bill Clinton in 1996, according to AP.
Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41760961/djt-stock-volatile-on-election-day-donald-trumps-media-company-reports-q3-earnings-growth-initiativ">DJT Stock Volatile On Election Day: Donald Trump&#8217;s Media Company Reports Q3 Earnings, Growth Initiatives</a></li>
</ul>
Image via Wikimedia Commons
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Kaustubh-Bagalkote" target="_blank" rel="noreferrer noopener">Kaustubh Bagalkote</a>

News

Global

Trump Wins Kentucky, Indiana — Harris Scores Vermont As Polls Begin To Close Across US

<h3 class="wp-block-heading">STOCKS RISES STEADILY ASTER SIGNAL</h3>
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="690" height="879" src="https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/05213424/Screen-Shot-2024-11-05-at-4.38.22-PM.png" alt="" class="wp-image-3000" style="width:auto;height:420px" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/05213424/Screen-Shot-2024-11-05-at-4.38.22-PM.png 690w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/05213424/Screen-Shot-2024-11-05-at-4.38.22-PM-235x300.png 235w" sizes="(max-width: 690px) 100vw, 690px" /></figure>
Atlassian Corp. (Team) today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions. 
Today, at 10:44 AM on November 5th, a significant trading signal occurred for Atlassian Corp (Team) as it demonstrated a Power Inflow at a price of $215.68 This indicator is crucial for traders who want to know directionally where institutions and so-called "smart money" moves in the market. They see the value of utilizing order flow analytics to guide their trading decisions. The Power Inflow points to a possible uptrend in Atlassian&#8217;s stock, marking a potential entry point for traders looking to capitalize on the expected upward movement. Traders with this signal closely watch for sustained momentum in Atlassian&#8217;s stock price, interpreting this event as a bullish sign.
<h3 class="wp-block-heading">Signal description</h3>
Order flow analytics, aka transaction or market flow analysis, separate and study both the retail and institutional volume rate of orders (flow). It involves analyzing the flow of buy and sell orders, along with size, timing, and other associated characteristics and patterns, to gain insights and make more informed trading decisions. This particular indicator is interpreted as a bullish signal by active traders.&nbsp;
The Power Inflow occurs within the first two hours of the market open and generally signals the trend that helps gauge the stock&#8217;s overall direction, powered by institutional activity in the stock, for the remainder of the day.&nbsp;
By incorporating order flow analytics into their trading strategies, market participants can better interpret market conditions, identify trading opportunities, and potentially improve their trading performance. But let's not forget that while watching smart money flow can provide valuable insights, it is crucial to incorporate effective risk management strategies to protect capital and mitigate potential losses. Employing a consistent and effective risk management plan helps traders navigate the uncertainties of the market in a more controlled and calculated manner, increasing the likelihood of long-term success
If you want to stay updated on the latest options trades for TEAM, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.&nbsp;
<a href="https://benzinga.com/apis?_gl=1&#x2A;1hlgn5i&#x2A;_ga&#x2A;MTY1NjE2NTYxMi4xNzE0NzQ4MTAy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDc0ODEwMi4xLjEuMTcxNDc0ODQyOC4wLjAuMA..">Market News and Data brought to you by Benzinga APIs</a> and include firms, like <a href="https://finitusa.com/en/">Finit USA</a>, responsible for parts of the data within this article. 
&#xA9; 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
<h3 class="wp-block-heading">After Market Close UPDATE:</h3>
The price at the time of the Power Inflow was $215.68. The returns on the High price ($222.29) and Close price ($221.54) after the Power Inflow were respectively 3.0% and 2.3%. That is why it is important to have a trading plan that includes Profit Targets and Stop Losses that reflect your risk appetite. In this case the high of the day and close were very close but that is not always the case
<h4 class="wp-block-heading">Past Performance Is Not Indicative Of Future Results</h4>

Signals

Markets

Trading Ideas

TRADEPULSE POWER INFLOW ALERT: ATLASSIAN CORP. CLASS A, TEAM,RECEIVES ALERT AND CLIMBS OVER 3% ON THE DAY.

Movers

S&P Futures Move Higher On Volume

Devon Energy Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVN#NYSE">DVN</a>) reported financial results for the third quarter after the bell on Tuesday. Here&#8217;s a look at the <a href="https://www.benzinga.com/pressreleases/24/11/g41757702/devon-energy-reports-third-quarter-2024-results-and-declares-quarterly-dividend">key metrics from the quarter</a>.
Q3 Earnings: Devon Energy reported third-quarter earnings of $1.30 per share, beating analyst <a href="https://www.benzinga.com/calendars/earnings">estimates</a> of $1.14 per share, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Devon said oil production reached 335,000 barrels per day during the quarter, about 4% ahead of the company&#8217;s previous guidance. 
The company said it generated $1.7 billion in operating cash flow and $786 million in free cash flow during the quarter before returning $431 million to shareholders. Devon repurchased $295 million of its common stock in the quarter and declared a fixed quarterly cash dividend of 22 cents per share, payable on Dec. 30 to shareholders of record as of Dec. 13.
&#8220;The Delaware Basin continues to be a great contributor to our success. The exceptional well productivity and cycle time improvements we continue to see in this basin contributed to production volumes surpassing our guidance while keeping capital expenditures below forecasted levels,&#8221; said Rick Muncrief, president and CEO of Devon Energy.
&#8220;Looking ahead to the remainder of 2024 and into 2025, we enhanced the quality and depth of our asset portfolio with the recent acquisition of Grayson Mill Energy. This transaction marks a major milestone, increasing our operating scale and strengthening our outlook for the fourth quarter and beyond.&#8221;
See Also: <a href="https://www.benzinga.com/news/earnings/24/11/41759387/bigbear-ai-stock-drops-after-worse-than-expected-q3-revenue-details">BigBear.ai Stock Drops After Worse-Than-Expected Q3 Revenue: Details</a>
Outlook: Devon raised its production forecast for the fourth quarter to a range of 811,000 to 830,000 barrels of oil equivalent per day. The company now expects the midpoint of its capital requirements to be $950 million in the fourth quarter, which includes $150 million of incremental capital requirements related to the Williston Basin acquisition.
Management will hold a conference call to further discuss these results at 11 a.m. ET on Wednesday. 
DVN Price Action: <a href="http://benzinga.com/quote/dvn">Devon Energy shares</a> initially traded up above the $40.50 level on the report before pulling back. The stock was down 0.23% after hours at $39.25 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

Earnings

Guidance

After-Hours Center

Devon Energy Q3 Earnings: EPS Beat, Production Forecast Raise And More

2024 Presidential Election Polls Close In The Following States: OH, NC, WV

Trump Media & Technology Shares Move Higher On Volume Over Past Few Minutes

As the election certification process is underway, House Speaker Mike Johnson (R-La.) has urged for calmness amidst the heightened emotions and misinformation.
What Happened: In response to EWTN News reporter Mark Irons&#8217; query about his role in certifying the election results, affirmed his commitment to uphold the Constitution and ensure a free and fair election, <a href="https://thehill.com/homenews/campaign/4973098-mike-johnson-certifying-election-results-everybody-needs-to-calm-down/">reported</a> The Hill.
Johnson played a pivotal role in the 2020 election, supporting former President Donald Trump&#8217;s challenge against President Joe Biden&#8217;s victory. He was key in formulating the legal argument for contesting Trump&#8217;s defeat, accusing some states of changing voting rules during the COVID-19 pandemic in violation of the Constitution.
See Also: <a href="https://www.benzinga.com/news/24/11/41701311/scaramucci-says-trump-should-be-taken-into-custody-over-alleged-threat-against-liz-cheney?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Scaramucci Says Trump &#8216;Should Be Taken Into Custody&#8217; Over Alleged Threat Against Liz Cheney</a>
Johnson downplayed claims of attempts to overturn the election results as &#8220;hyperbole and madness&#8221;. He also criticized the media for overreacting to Trump&#8217;s &#8220;secret&#8221; mentioned at his Madison Square Garden rally, which Johnson clarified was a voter mobilization effort, not a hidden agenda.
&#8220;There's just too much emotion, too much misinformation out there. Everybody needs to calm down,&#8221; said Johnson.
Johnson urged citizens to perform their &#8220;civic duty&#8221; and participate in an &#8220;American election&#8221; that will be certified. He expressed confidence in a second Trump term and a Republican-controlled Congress, stating the election will be &#8220;too big to rig&#8221;.
&#8220;I think President Trump's going to win today and I think we're going to win the Senate and the House, so we're excited,&#8221; said the House Speaker.
At the time of writing, polls were beginning to close across the U.S. with AP declaring Indian, Kentucky for Trump, and Vermont for Kamala Harris.
Why It Matters: Johnson&#8217;s call for calm comes amidst a backdrop of a <a href="https://www.benzinga.com/general/politics/24/11/41728436/trump-vs-harris-2024-election-deadlocked-final-emerson-poll-shows-one-candidate-with-small-edge-">closely contested</a> 2024 U.S. presidential election between Vice President Harris and former President Trump. As per a Benzinga report, the election remains one of the closest in history, with a tight race expected between the two candidates.
Several election-related legal battles have <a href="https://www.benzinga.com/government/24/11/41761179/supreme-court-could-step-in-if-2024-election-remains-deadlocked">already reached the Supreme Court</a>, including a decision to allow Virginia&#8217;s removal of over 1,600 voters from its rolls and rulings affecting candidates and voters in battleground states. This has raised concerns over the potential involvement of the U.S. Supreme Court in determining the outcome of the election.
Image via Shutterstock
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

Mike Johnson Urges Calm On Result Certification: The Election Is 'Too Big To Rig'

2024 Presidential Election Polls Close In The Following States: GA, IN, KY, SC, VA, VT

Seaport Global analyst Tom Curran initiates coverage on First Solar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) with a Neutral rating.

Initiation

Analyst Ratings

FSLR

Seaport Global Initiates Coverage On First Solar with Neutral Rating

Scotiabank analyst Greg Harrison maintains Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Sector Perform and raises the price target from $480 to $486.

Price Target

VRTX

Scotiabank Maintains Sector Perform on Vertex Pharmaceuticals, Raises Price Target to $486

Scotiabank analyst Greg Harrison maintains Disc Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRON#NASDAQ">IRON</a>) with a Sector Outperform and raises the price target from $62 to $70.

IRON

Scotiabank Maintains Sector Outperform on Disc Medicine, Raises Price Target to $70

Scotiabank analyst Mario Saric maintains Brookfield Asset Mgmt (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAM#NYSE">BAM</a>) with a Sector Outperform and raises the price target from $55.5 to $59.5.

Scotiabank Maintains Sector Outperform on Brookfield Asset Mgmt, Raises Price Target to $59.5

Scotiabank analyst Andres Coello maintains TIM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TIMB#NYSE">TIMB</a>) with a Sector Outperform and lowers the price target from $24.8 to $23.2.

TIMB

Scotiabank Maintains Sector Outperform on TIM, Lowers Price Target to $23.2

Scotiabank analyst Maher Yaghi maintains BCE (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BCE#TSX">BCE</a>) with a Sector Perform and lowers the price target from C$50.5 to C$47.5.

TSX:BCE

Scotiabank Maintains Sector Perform on BCE, Lowers Price Target to C$47.5

Citigroup analyst Christopher Danely maintains GLOBALFOUNDRIES (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GFS#NASDAQ">GFS</a>) with a Neutral and lowers the price target from $45 to $40.

Citigroup Maintains Neutral on GLOBALFOUNDRIES, Lowers Price Target to $40

NVIDIA Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) passed Apple, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) to become the world's largest publicly traded <a href="https://www.benzinga.com/news/24/11/41751557/nvidia-takes-short-lived-lead-over-apple-in-valuation">company on Tuesday. </a>
The Details: Nvidia ended Tuesday's trading session with a market capitalization of $3.43 trillion, slightly <a href="https://www.benzinga.com/news/24/11/41751557/nvidia-takes-short-lived-lead-over-apple-in-valuation">edging out </a>Apple&#8217;s $3.38 trillion valuation, according to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>. The semiconductor giant's dominance in the artificial intelligence chip market has fueled its exponential growth of more than 200% over the past year.&nbsp;
Read More: <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/11/41724410/nvidia-joining-dow-jones-industrial-average-where-tech-giant-ranks-in-the-index-why-sh">Nvidia Joining Dow Jones Industrial Average: Where Tech Giant Ranks In The Index, Why Sherwin-Williams Addition Could Be More Important</a>
Nvidia briefly passed Apple <a href="https://www.benzinga.com/news/24/06/39386946/microsoft-apple-step-aside-nvidia-is-now-the-most-valuable-public-company-in-the-world">in market cap </a>in June before sliding over the summer.<a href="https://www.cnbc.com/quotes/MSFT/"> </a>Nvidia&#8217;s ascent to the top highlights the growing importance of AI technology and the pivotal role that Nvidia's specialized hardware plays in its development.&nbsp;
Despite Nvidia's remarkable growth over the past year, analysts remain bullish on the company's growth ahead. The three most recent analyst ratings were released by BofA Securities, Goldman Sachs and Morgan Stanley in October with an average price target of $163.33 between the three. There&#8217;s an implied 17.04% upside for Nvidia stock from these analyst ratings.
Last Friday, S&amp;P Dow Jones announced that Nvidia <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/11/41724410/nvidia-joining-dow-jones-industrial-average-where-tech-giant-ranks-in-the-index-why-sh">is joining the Dow Jones Industrial Average on Nov. 8 </a>replacing Intel Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) and joining Apple in the blue-chip index. 
NVDA Price Action: According to data from Benzinga Pro, Nvidia shares ended Tuesday's session 2.84% higher at $139.91.&nbsp;
Read Also:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41690154/shock-october-jobs-report-leaves-fed-in-tight-spot-experts-say-interest-rate-cuts-a">Shock October Jobs Report Leaves Fed In &#8216;Tight Spot:&#8217; Experts Say Interest Rate Cuts Ahead</a></li>
</ul>
Image: Shutterstock

Large Cap

Tech

AAPL

INTC

NVDA

Nvidia Blows Past Apple To Become World's Most Valuable Company

Lake Street analyst Mark Argento maintains Gaia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GAIA#NASDAQ">GAIA</a>) with a Buy and raises the price target from $6 to $7.

GAIA

Lake Street Maintains Buy on Gaia, Raises Price Target to $7

Lake Street analyst Thomas Flaten maintains Castle Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSTL#NASDAQ">CSTL</a>) with a Buy and raises the price target from $34 to $40.

CSTL

Lake Street Maintains Buy on Castle Biosciences, Raises Price Target to $40

Lake Street analyst Jaeson Schmidt maintains NAPCO Security Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSSC#NASDAQ">NSSC</a>) with a Buy and lowers the price target from $60 to $41.

NSSC

Lake Street Maintains Buy on NAPCO Security Techs, Lowers Price Target to $41

Elicio Therapeutics announces proposed public offering

Elicio Therapeutics (ELTX) just unveiled an update. Elicio Therapeutics, Inc. has shared encouraging preliminary results from the AMPLIFY-7P Phase ...

Elicio Therapeutics' Promising Early Results in Cancer Vaccine Trial

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are a hot topic on Friday and we&rsquo;re breaking down all of the latest news sending shares higher and lower this morning!



Moving stocks are new orders and agreements, earnings reports, public offerings and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>African Agriculture (NASDAQ:<a href="https://investorplace.com/stock-quotes/aagr-stock-quote/">AAGR</a>) stock is rocketing more than 76% alongside heavy pre-market trading.</li>



<li>Cosmos Health (NASDAQ:<a href="https://investorplace.com/stock-quotes/cosm-stock-quote/">COSM</a>) shares are soaring over 56% on a <a href="https://www.nasdaq.com/press-release/cosmos-health-signs-exclusive-distribution-agreement-pharmalink-its-sky-premium-life">distribution agreement and purchase order</a>.</li>



<li>Ocean Power Technologies (NYSEMKT:<a href="https://investorplace.com/stock-quotes/optt-stock-quote/">OPTT</a>) stock is surging more than 55% after <a href="https://www.nasdaq.com/press-release/ocean-power-technologies-signs-oem-agreement-key-maritime-technology-provider">signing an OEM agreement</a>.</li>



<li>CARISMA Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/carm-stock-quote/">CARM</a>) shares are gaining over 41% on a dr<a href="https://www.prnewswire.com/news-releases/carisma-therapeutics-announces-nomination-of-first-in-vivo-car-m-development-candidate-for-hepatocellular-carcinoma-under-collaboration-with-moderna-302185002.html">ug development candidate nomination</a>.</li>



<li>Actelis Networks (NASDAQ:<a href="https://investorplace.com/stock-quotes/asns-stock-quote/">ASNS</a>) stock is rising more than 19% on <a href="https://www.investing.com/news/company-news/actelis-secures-300k-order-for-italian-transport-project-93CH-3500256">a $300,000 order</a>.</li>



<li>Emerson Radio (NYSEMKT:<a href="https://investorplace.com/stock-quotes/msn-stock-quote/">MSN</a>) shares are heading over 19% higher witout any clear news.</li>



<li>Infinera (NASDAQ:<a href="https://investorplace.com/stock-quotes/infn-stock-quote/">INFN</a>) stock is increasing more than 19% on a <a href="https://www.marketwatch.com/story/infineras-stock-rockets-22-after-2-3-billion-purchase-by-nokia-2125f317">$2.3 billion purchase order</a>.</li>



<li>ECD Automotive Design (NASDAQ:<a href="https://investorplace.com/stock-quotes/ecda-stock-quote/">ECDA</a>) shares are climbing over 12% alongside its <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318421650&amp;type=PDF&amp;symbol=ECDA&amp;cdn=c600c816f00588b364ea61c3034e71c9&amp;companyName=ECD+Automotive+Design+Inc.&amp;formType=10-Q&amp;formDescription=General+form+for+quarterly+reports+under+Section+13+or+15%28d%29&amp;dateFiled=2024-06-27">latest earnings report</a>.</li>



<li>American Battery Tech (NASDAQ:<a href="https://investorplace.com/stock-quotes/abat-stock-quote/">ABAT</a>) stock is jumping more than 11% on Friday morning.</li>



<li>Connexa Sports Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/yyai-stock-quote/">YYAI</a>) shares are up over 10% following a <a href="https://www.nasdaq.com/press-release/connexa-announces-1-20-reverse-split-remedy-bid-price-delisting-notice-2024-06-25">reverse stock split to regain compliance</a>.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Nexalin Technology (NASDAQ:<a href="https://investorplace.com/stock-quotes/nxl-stock-quote/">NXL</a>) stock is plummeting more than 33% after <a href="https://www.nasdaq.com/press-release/nexalin-technology-announces-pricing-52-million-public-offering-2024-06-27">pricing a public offering</a>.</li>



<li>Elicio Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/eltx-stock-quote/">ELTX</a>) shares are diving over 26% on a <a href="https://www.nasdaq.com/press-release/elicio-therapeutics-announces-proposed-public-offering-2024-06-27">proposed public offering</a>.</li>



<li>Accolade (NASDAQ:<a href="https://investorplace.com/stock-quotes/accd-stock-quote/">ACCD</a>) stock is tumbling more than 26% <a href="https://finance.yahoo.com/news/accolade-accd-reports-q1-loss-211502651.html">alongside a Q1 earnings miss</a>.</li>



<li>Anitra (NYSEMKT:<a href="https://investorplace.com/stock-quotes/aztr-stock-quote/">AZTR</a>) shares are taking an over 24% beating on Friday morning.</li>



<li>Inspire Veterinary (NASDAQ:<a href="https://investorplace.com/stock-quotes/ivp-stock-quote/">IVP</a>) stock is dropping more than 20% this morning.</li>



<li>Gain Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/ganx-stock-quote/">GANX</a>) shares are falling over 19% after <a href="https://www.nasdaq.com/press-release/gain-therapeutics-inc-appoints-gene-mack-interim-ceo-2024-06-27">announcing an interim CEO</a>.</li>



<li>Assure (NASDAQ:<a href="https://investorplace.com/stock-quotes/ionm-stock-quote/">IONM</a>) stock is decreasing more than 16% <a href="https://investorplace.com/2024/06/why-is-assure-ionm-stock-up-191-today/">after a rally yesterday</a>.</li>



<li>American Well (NYSE:<a href="https://investorplace.com/stock-quotes/amwl-stock-quote/">AMWL</a>) shares are slipping over 14% on <a href="https://www.stocktitan.net/news/AMWL/amwell-announces-reverse-stock-4im1mwzldvbn.html">reverse stock split news</a>.</li>



<li>Royalty Management (NASDAQ:<a href="https://investorplace.com/stock-quotes/rmco-stock-quote/">RMCO</a>) stock is sliding more than 14% today.</li>



<li>Nike (NYSE:<a href="https://investorplace.com/stock-quotes/nke-stock-quote/">NKE</a>) shares close out our pre-market stock movers down over 14% on <a href="https://finance.yahoo.com/news/nike-stock-sinks-after-company-projects-larger-sales-decline-than-expected-in-2025-192129443.html">an expected sales declinein 2025</a>.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/06/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-friday-june-28th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Elicio Therapeutics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/eltx-stock-quote/">ELTX</a>) stock is falling on Friday after the clinical-stage biotechnology company <a href="https://www.nasdaq.com/press-release/elicio-therapeutics-announces-proposed-public-offering-2024-06-27">announced a proposed public offering</a>.



Elicio Therapeutics has announced its plans for a public offering that will include shares of ELTX stock, warrants to purchase additional shares and pre-funded warrants. What the company doesn&rsquo;t reveal is the size and pricing of the offering.



Elicio Therapeutics says that it intends to use the funds from the offering for &ldquo;the advancement of its development pipeline.&rdquo; It will also use the money for working capital and general corporate purposes.



<h2>What This Means for ELTX Stock</h2>



With this public offering will come an increase in the total number of ELTX shares outstanding. That will also result in the stakes of current investors in Elicio Therapeutics being diluted. That helps explain why shares of ELTX stock are falling on Friday.



To go along with that, investors are likely wary about the pricing of the offering. While it hasn&rsquo;t been announced yet, it&rsquo;s likely to be below the current price of the company&rsquo;s stock. This will likely result in further drops for ELTX shares once the price is announced.



ELTX stock is down 36.2% as of Friday morning. That comes with 18,000 shares traded, as compared to a daily average of about 46,000 shares.



We have more of the most recent stock market stories worth reading about on Friday!



Our coverage includes all of the hottest market news traders need to know about today! That includes everything happening with shares of Nexalin Technology&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/nxl-stock-quote/">NXL</a>) stock, Cosmos Health&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/cosm-stock-quote/">COSM</a>) stock and African Agriculture&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/aagr-stock-quote/">AAGR</a>) stock this morning. You can catch up on all of these matters by checking out the links below!



<h2>More Stock Market News for Friday</h2>



<ul><li><a href="https://investorplace.com/2024/06/why-is-nexalin-technology-nxl-stock-down-35-today/">Why Is Nexalin Technology (NXL) Stock Down 35% Today?</a></li>



<li><a href="https://investorplace.com/2024/06/why-is-cosmos-health-cosm-stock-up-65-today/">Why Is Cosmos Health (COSM) Stock Up 65% Today?</a></li>



<li><a href="https://investorplace.com/2024/06/why-is-african-agriculture-aagr-stock-up-55-today/">Why Is African Agriculture (AAGR) Stock Up 55% Today?</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/06/why-is-elicio-therapeutics-eltx-stock-down-36-today/">Why Is Elicio Therapeutics (ELTX) Stock Down 36% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Elicio Therapeutics (ELTX) Stock Down 36% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Elicio Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/eltx-stock-quote/">ELTX</a>) just reported results for the second quarter of 2024.<ul><li>Elicio Therapeutics reported earnings per share of -64 cents. This was above the analyst estimate for EPS of -96 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/eltx-stock-earnings-elicio-therapeutics-for-q2-of-2024/">ELTX Stock Earnings: Elicio Therapeutics Beats EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ELTX Stock Earnings: Elicio Therapeutics Beats EPS for Q2 2024

Elicio Therapeutics GAAP EPS of -$0.64

Analyst Robert Burns from H.C. Wainwright reiterated a Buy rating on Elicio Therapeutics (ELTX – Research Report) and keeping the price target at $...

Elicio Therapeutics: A Strong Buy on Improved Financials and Promising Clinical Trials

An announcement from Elicio Therapeutics (ELTX) is now available. Brian Piekos has announced his resignation as CFO and Treasurer of Elicio Therape...

Elicio Therapeutics CFO Brian Piekos Resigns Amicably

An announcement from Elicio Therapeutics ( ($ELTX) ) is now available. Elicio Therapeutics has appointed Robert Connelly as its Principal Accountin...

Elicio Therapeutics Appoints Robert Connelly as Financial Officer

JonesResearch analyst Soumit Roy initiated coverage of Elicio Therapeutics (ELTX) with a Buy rating and $9 price target Elicio's off-the-shelf canc...

Elicio Therapeutics initiated with a Buy at JonesResearch

AAGR

ABAT

ACCD

AMWL

ASNS

AZTR

CARM

COSM

ECDA

ELTX

GANX

INFN

IONM

OPTT

RMCO

YYAI

Screenshot 2024-06-07 at 5.22.00 PM

Biotech

Elicio Therapeutics Unveils Promising Phase 1a Data For ELI-002 7P In mKRAS Tumors

Screenshot 2024-04-10 at 5.39.01 PM

Elicio Therapeutics (NASDAQ: ELTX) Makes Strides In Growing Cancer Vaccination Industry

Screenshot 2024-04-04 at 5.26.54 PM

Unlocking The Power Of Immunotherapy: Elicio Therapeutics&#39; (NASDAQ: ELTX) Novel AMP Platform

Health Care

Press Releases

Elicio Therapeutics Announces Preliminary Disease-Free Survival analysis from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P

Elicio Therapeutics Announces Proposed Public Offering

Financing

Elicio Therapeutics Announces Pricing of $11.5 Million Underwritten Public Offering

Elicio Therapeutics Announces Closing of Private Placement of $20.0 Million Convertible Note

Elicio Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Elicio Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Elicio Therapeutics Announces Three Upcoming Presentations Focused on its Lymph Node Targeted, mKRAS-Specific Amphiphile Vaccines

Elicio Therapeutics Reports Inducement Grants

Elicio Therapeutics to Present Clinical Data at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting and Stand Up to Cancer (SU2C) Innovation Summit

Comments

Elicio Therapeutics

Elicio Therapeutics (ELTX) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO